계명대학교 의학도서관 Repository

Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer

Metadata Downloads
Author(s)
김진영도영록박건욱송홍석
Alternative Author(s)
Kim, Jin YoungDo, Young RokPark, Keon UkSong, Hong Suk
Publication Year
2011
Abstract
Objective : The present study was conducted to evaluate the efficacy and safety of a combination regimen of S-1, paclitaxel plus cisplatin in patients with advanced gastric cancer.
Methods : Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous paclitaxel 80 mg/m2 plus cisplatin 30 mg/m2 on days 1, 8 and S-1 35 mg/m2 orally twice daily on days 1–14 based on a 3-week cycle.
Results : Forty-four patients were enrolled in the current study, among whom 38 were assessable for efficacy and all assessable for toxicity. Two complete response and 24 partial responses were confirmed, giving an overall response rate of 59.1%. At a median follow-up of 11.4 months, the median time to progression and median overall survival was 9.4 (95% CI 6.8–12.1) months and 11.2 (95% CI 7.6–14.8) months, respectively. Grade 3/4 neutropenia occurred in 45 events (20.9%) and febrile neutropenia was observed in five events (2.3%). The common non-hematologic toxicity was nausea (grade 1/2, 27.2%) and diarrhea (grade 1/2, 9.0%).
Conclusion : The combination of S-1, paclitaxel and cisplatin was found to be well tolerated and effective in patients with advanced gastric cancer.
Keywords : S-1 – Paclitaxel – Cisplatin – Chemotherapy – Gastric cancer
Department
Dept. of Internal Medicine (내과학)
Publisher
School of Medicine
Citation
Cancer Chemotherapy and Pharmacology, Vol.67(3) : 527-532, 2011
Type
Article
ISSN
0344-5704
DOI
10.1007/s00280-010-1353-6
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/35289
Authorize & License
  • AuthorizeOpen
  • EmbargoForever
Files in This Item:

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.